FDA approves juxtapid for rare cholesterol disorder

FDA approves juxtapid for rare cholesterol disorder
The U.S. Food and Drug Administration has approved the orphan drug Juxtapid (lomitapide) for patients with homozygous familial hypercholesterolemia, for use in combination with a low-fat diet and other lipid lowering treatments, according to a Dec. 26 press release.

(HealthDay)—The U.S. Food and Drug Administration has approved the orphan drug Juxtapid (lomitapide) for patients with homozygous familial hypercholesterolemia (HoFH), for use in combination with a low-fat diet and other lipid lowering treatments, according to a Dec. 26 press release.

Juxtapid, an orphan drug marketed by Cambridge, Mass.-based Aegerion Pharmaceuticals Inc., was evaluated in a trial including 29 patients with HoFH, an inherited disorder of high low-density lipoprotein (LDL) cholesterol. For those who tolerated the drug, levels of LDL cholesterol decreased by approximately one-half during the first 26 weeks.

Juxtapid, a capsule taken once a day, without food, at least two hours after the evening meal, carries a boxed warning regarding a serious risk of . Juxtapid also decreases the absorption of fat-soluble nutrients and, consequently, patients should take supplements that contain fat-soluble nutrients and essential fatty acids while taking Juxtapid. Juxtapid also interacts with several other medications.

"Juxtapid, in addition to diet changes and other cholesterol-lowering treatments, is a new option for those suffering with HoFH and the serious resulting from this condition," Eric Colman, M.D., deputy director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Monthly shot lowers cholesterol 66 percent: study

Mar 26, 2012

A monthly injection of an experimental drug made by the US biotech firm Amgen reduced patients' cholesterol by up to 66 percent, according to a small study described at a US cardiology conference.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.